Condition Directory

Breast Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Breast Cancer. Browse Breast Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 15, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7089

Shown on this page

Current sort

How Breast Cancer studies are organized in the registry

Breast cancer listings are usually subtype-specific: receptor status appears directly in titles and condition fields, so subtype terms narrow results far better than stage words alone. Many studies also restrict to either early-stage or metastatic settings, which is visible in the title or eligibility section of the official record.

Terms that often appear in related listings

triple-negative HER2-positive hormone receptor-positive metastatic breast cancer

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 925–936 of 7,089 matching trials for Breast Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Breast Cancer
Interventions: TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells, Trastuzumab deruxtecan (T-DXd), Rimiducid; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Ipatasertib, Fulvestrant, Aromatase Inhibitor, Palbociclib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Breast Neoplasms, Breast Cancer Female, Neoplasms
Interventions: contrast-enhanced mammography; Device
Lead sponsor: Wendie Berg; Other
Eligibility: 30 Years to 79 Years · Female only
Enrollment: 1,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2031
U.S. locations: 6
States / cities: Bethel Park, Pennsylvania • Cranberry Township, Pennsylvania • Monroeville, Pennsylvania + 2 more

Conditions: Breast Cancer Metastatic, Advanced Breast Cancer, Stage 4 Breast Cancer, Stage IV (Metastatic) Breast Cancer
Interventions: Decision Support Tool; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Brooklyn, New York • Flushing, New York • New York, New York

Conditions: HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Ovarian Cancer, NSCLC, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer (TNBC)
Interventions: NRM-823; Drug
Lead sponsor: Normunity AccelCo, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 13 more

Conditions: ER+ HER2- Advanced Breast Cancer
Interventions: AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus, AZD9833 with abemaciclib, AZD9833 with capivasertib, AZD9833 with ribociclib, AZD9833 with anastrozole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 5
States / cities: Aurora, Colorado • Sarasota, Florida • Philadelphia, Pennsylvania + 2 more

Conditions: Breast Cancer Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions: Elacestrant, DC1 native/mutated ESR1; Drug · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: p16INK4a mRNA level assessment, organ-specific protein signatures assessment; Diagnostic Test
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 22 Years to 66 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2026
U.S. locations: 11
States / cities: Hays, Kansas • Kansas City, Kansas • Overland Park, Kansas + 4 more

Conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Endometrial Cancer, History of Cancer
Interventions: Publicly available genetic testing resources, Virtual genetics navigator, Motivational interviewing (MI); Other · Behavioral
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 793 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Cancer Screening
Interventions: MyMammogram decision aid; Behavioral
Lead sponsor: Trustees of Dartmouth College; Other
Eligibility: 39 Years to 49 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Hanover, New Hampshire

Conditions: Breast Cancer Surgery
Interventions: Nipple Sparing Mastectomy (NSM), Skin-Sparing Mastectomy (SSM), Total (Simple) Mastectomy; Procedure
Lead sponsor: Sir Mortimer B. Davis - Jewish General Hospital; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 4,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: New Haven, Connecticut • Boston, Massachusetts • New York, New York + 2 more

About this Breast Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Breast Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Breast Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Breast Cancer clinical trials

How Breast Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Biennial CEM in Women With a Personal History of Breast Cancer

Decision Support Tool for Patients With Advanced Breast Cancer

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

A Novel Approach Utilizing Organ Specific Age Proteomics

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

Michigan Genetic Hereditary Testing (MiGHT)

Adapting a Mammography Decision Aid to Support Women Living in a Community Contaminated by PFAS

Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer

About this Breast Cancer clinical trials directory page